Nombre del producto:6-Bromo-4-chloro-7-fluoro-3-nitroquinoline

IUPAC Name:6-bromo-4-chloro-7-fluoro-3-nitroquinoline

CAS:853908-81-3
Fórmula molecular:C9H3BrClFN2O2
Pureza:95%+
Número de catálogo:CM223089
Peso molecular:305.49

Unidad de embalaje Stock disponible Precio($) Cantidad
CM223089-1g in stock ũƦNJ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :853908-81-3
Fórmula molecular:C9H3BrClFN2O2
Punto de fusión:-
Código de sonrisas:O=[N+](C1=C(Cl)C2=CC(Br)=C(F)C=C2N=C1)[O-]
Densidad:
Número de catálogo:CM223089
Peso molecular:305.49
Punto de ebullición:387.0±37.0°C at 760 mmHg
Nº Mdl:
Almacenamiento:Keep in inert atmosphere, store in freezer, under -20°C.

Category Infos

Quinolines
Quinolines are an important class of biologically active heterocyclic compounds, and their derivatives usually exhibit a variety of biological activities. They can be used as antimalarial drugs and in the preparation of other antimalarial drugs. Other important activities of quinoline derivatives include inhibitory activity against EGFR-TK and antipsychotic activity. Futhermore, quinoline scaffolds are present in various drug molecules, including the antimalarial drugs aablaquine, chloroquine, mefloquine and primaquine, and the antibacterial agents gatifloxacin, levofloxacin, and moxifloxacin.
Quinoline Price
if you have any question on quinoline price, we will give the professional answers to your short questions.

Column Infos

XRD-0394
XRad Therapeutics announced that the first patient has been dosed in the company’s Phase 1a trial evaluating XRD-0394 in combination with radiation therapy for the treatment of metastatic, locally-advanced or recurrent solid tumors.
XRD-0394, is a first-in-class dual inhibitor of ataxia-telangiectasia mutated (ATM) and DNA-dependent protein kinase (DNA-PK). Initial development efforts are focused on evaluating XRD-0394’s ability to enhance radiation therapy when used in combination. In parallel, the company is exploring the potential benefits of using XRad’s dual kinase inhibitors in combination with targeted radionuclides, immune checkpoint inhibitors, polyadenosine diphosphate-ribose polymerase inhibitors and antibody drug conjugates.

Related Products